Zostavax Coverage Under Part D Sets Precedent For New Vaccines
Executive Summary
Merck is working to gain CMS support for a web-based billing system that would facilitate Part D coverage for its recently-introduced shingles vaccine Zostavax
You may also be interested in...
Merck Q3: Zostavax Nears Part D Hurdles, Gardasil Sales On Fast Track
Merck will seek to drive continued growth of its shingles vaccine Zostavax through promotional activity and efforts to facilitate reimbursement, the firm said
Merck Q3: Zostavax Nears Part D Hurdles, Gardasil Sales On Fast Track
Merck will seek to drive continued growth of its shingles vaccine Zostavax through promotional activity and efforts to facilitate reimbursement, the firm said
Therapeutic Biologics Approvals Up In 2006, Overall BLA Approvals Steady
Overall 2006 biological license application approvals held steady from 2005 at 10 approvals, but the year saw a significant increase in approvals of therapeutic biologics